Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin

Yanan Fang, Corinne M. Linardic, D. Ashley Richardson, Wen Cai, Mohammad Behforouz, Robert T. Abraham

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities. However, preclinical development of lavendamycin as an anticancer agent was halted due to the poor aqueous solubility and relatively nonspecific cytotoxic activity of this compound. In this report, we have examined the cytotoxic activities of a series of novel lavendamycin analogues. The cytotoxic activities of these compounds were evaluated in clonogenic survival assays with A549 lung carcinoma cells. Compounds bearing an amide or amine substituent at the R3 position were the most potent inhibitors of colony formation. MB-97, the most active member of this subgroup, decreased clonogenic outgrowth by 70% at a concentration of 10 nM. Treatment of A549 cells with MB-97 led to an increase in p53 protein expression and phosphorylation and a concomitant increase in the expression of the p53 target gene, p21. Exposure of p53-positive cells to MB-97 triggered cell cycle arrest in G1 and G2 phases but induced a selective G 2-phase arrest in p53-negative cells. MB-97 treatment also induced a higher level of apoptosis in p53-null cells relative to their p53-positive counterparts. Finally, MB-97 showed significant cytotoxic activity in the National Cancer Institute's panel of 60 cancer cell lines and antitumor activity in vivo in hollow fiber tumorigenesis assays.

Original languageEnglish (US)
Pages (from-to)517-526
Number of pages10
JournalMolecular Cancer Therapeutics
Volume2
Issue number6
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Antineoplastic Agents
Null Lymphocytes
National Cancer Institute (U.S.)
G2 Phase
p53 Genes
G1 Phase
Cell Cycle Checkpoints
Amides
Solubility
Amines
Carcinogenesis
Phosphorylation
Apoptosis
Carcinoma
Cell Line
Lung
lavendamycin
Neoplasms
Proteins
A549 Cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Drug Discovery
  • Pharmacology

Cite this

Fang, Y., Linardic, C. M., Richardson, D. A., Cai, W., Behforouz, M., & Abraham, R. T. (2003). Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. Molecular Cancer Therapeutics, 2(6), 517-526.

Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. / Fang, Yanan; Linardic, Corinne M.; Richardson, D. Ashley; Cai, Wen; Behforouz, Mohammad; Abraham, Robert T.

In: Molecular Cancer Therapeutics, Vol. 2, No. 6, 06.2003, p. 517-526.

Research output: Contribution to journalArticle

Fang, Y, Linardic, CM, Richardson, DA, Cai, W, Behforouz, M & Abraham, RT 2003, 'Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin', Molecular Cancer Therapeutics, vol. 2, no. 6, pp. 517-526.
Fang, Yanan ; Linardic, Corinne M. ; Richardson, D. Ashley ; Cai, Wen ; Behforouz, Mohammad ; Abraham, Robert T. / Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. In: Molecular Cancer Therapeutics. 2003 ; Vol. 2, No. 6. pp. 517-526.
@article{1d84bd02038d47528260a7137069d713,
title = "Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin",
abstract = "Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities. However, preclinical development of lavendamycin as an anticancer agent was halted due to the poor aqueous solubility and relatively nonspecific cytotoxic activity of this compound. In this report, we have examined the cytotoxic activities of a series of novel lavendamycin analogues. The cytotoxic activities of these compounds were evaluated in clonogenic survival assays with A549 lung carcinoma cells. Compounds bearing an amide or amine substituent at the R3 position were the most potent inhibitors of colony formation. MB-97, the most active member of this subgroup, decreased clonogenic outgrowth by 70{\%} at a concentration of 10 nM. Treatment of A549 cells with MB-97 led to an increase in p53 protein expression and phosphorylation and a concomitant increase in the expression of the p53 target gene, p21. Exposure of p53-positive cells to MB-97 triggered cell cycle arrest in G1 and G2 phases but induced a selective G 2-phase arrest in p53-negative cells. MB-97 treatment also induced a higher level of apoptosis in p53-null cells relative to their p53-positive counterparts. Finally, MB-97 showed significant cytotoxic activity in the National Cancer Institute's panel of 60 cancer cell lines and antitumor activity in vivo in hollow fiber tumorigenesis assays.",
author = "Yanan Fang and Linardic, {Corinne M.} and Richardson, {D. Ashley} and Wen Cai and Mohammad Behforouz and Abraham, {Robert T.}",
year = "2003",
month = "6",
language = "English (US)",
volume = "2",
pages = "517--526",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin

AU - Fang, Yanan

AU - Linardic, Corinne M.

AU - Richardson, D. Ashley

AU - Cai, Wen

AU - Behforouz, Mohammad

AU - Abraham, Robert T.

PY - 2003/6

Y1 - 2003/6

N2 - Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities. However, preclinical development of lavendamycin as an anticancer agent was halted due to the poor aqueous solubility and relatively nonspecific cytotoxic activity of this compound. In this report, we have examined the cytotoxic activities of a series of novel lavendamycin analogues. The cytotoxic activities of these compounds were evaluated in clonogenic survival assays with A549 lung carcinoma cells. Compounds bearing an amide or amine substituent at the R3 position were the most potent inhibitors of colony formation. MB-97, the most active member of this subgroup, decreased clonogenic outgrowth by 70% at a concentration of 10 nM. Treatment of A549 cells with MB-97 led to an increase in p53 protein expression and phosphorylation and a concomitant increase in the expression of the p53 target gene, p21. Exposure of p53-positive cells to MB-97 triggered cell cycle arrest in G1 and G2 phases but induced a selective G 2-phase arrest in p53-negative cells. MB-97 treatment also induced a higher level of apoptosis in p53-null cells relative to their p53-positive counterparts. Finally, MB-97 showed significant cytotoxic activity in the National Cancer Institute's panel of 60 cancer cell lines and antitumor activity in vivo in hollow fiber tumorigenesis assays.

AB - Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities. However, preclinical development of lavendamycin as an anticancer agent was halted due to the poor aqueous solubility and relatively nonspecific cytotoxic activity of this compound. In this report, we have examined the cytotoxic activities of a series of novel lavendamycin analogues. The cytotoxic activities of these compounds were evaluated in clonogenic survival assays with A549 lung carcinoma cells. Compounds bearing an amide or amine substituent at the R3 position were the most potent inhibitors of colony formation. MB-97, the most active member of this subgroup, decreased clonogenic outgrowth by 70% at a concentration of 10 nM. Treatment of A549 cells with MB-97 led to an increase in p53 protein expression and phosphorylation and a concomitant increase in the expression of the p53 target gene, p21. Exposure of p53-positive cells to MB-97 triggered cell cycle arrest in G1 and G2 phases but induced a selective G 2-phase arrest in p53-negative cells. MB-97 treatment also induced a higher level of apoptosis in p53-null cells relative to their p53-positive counterparts. Finally, MB-97 showed significant cytotoxic activity in the National Cancer Institute's panel of 60 cancer cell lines and antitumor activity in vivo in hollow fiber tumorigenesis assays.

UR - http://www.scopus.com/inward/record.url?scp=1542439672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542439672&partnerID=8YFLogxK

M3 - Article

C2 - 12813130

AN - SCOPUS:1542439672

VL - 2

SP - 517

EP - 526

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -